Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2241 to 2250 of 2621 total matches.
Infliximab (Remicade) for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Feb 26, 1999 (Issue 1047)
mg/kg of the drug, 13 (48%) went into remission, compared to 1 of 25 (4%) of those given
placebo ...
Infliximab, a monoclonal antibody that inhibits tumor necrosis factor, has received an accelerated approval from the FDA for intravenous treatment of moderate to severe Crohn's disease refractory to other medical treatment.
Laser Hair Removal
The Medical Letter on Drugs and Therapeutics • Jul 30, 1999 (Issue 1058)
Aesth Dermatol Cosmet Surg, 1:3, 1999).
MECHANISM OF ACTION — Several laser systems are used for hair ...
A long-pulse ruby laser (EpiLaser), has been cleared by the FDA for use in "permanent hair reduction."
Phytoestrogens
The Medical Letter on Drugs and Therapeutics • Feb 21, 2000 (Issue 1072)
at 1000 Main Street, New Rochelle, NY
10801-7537. Subscription fees: 1 year, $49.00; 2 years, $82.00; 3 ...
Phytoestrogens, plant compounds that are converted to estrogens in the gut, are widely promoted as "natural"substitutes for estrogen in hormone replacement therapy.
Update on Glucosamine For Osteoarthritis
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001 (Issue 1120)
10801-7537. Subscription fees: 1 year, $55.00; 2 years, $94.00; 3 years, $132.00 ($27.50—U.S. Funds—per ...
Since the last Medical Letter article on glucosamine for osteoarthritis (vol.39, page 91, September 26, 1997), more data have become available. Glucosamine is available in US pharmacies and health food stores as sulfate, hydrochloride or n-acetyl salt.
Dexmethylphenidate (Focalin) For ADHD
The Medical Letter on Drugs and Therapeutics • May 13, 2002 (Issue 1130)
Rochelle,
NY 10801-7537. Subscription fees: 1 year, $55.00; 2 years, $94.00; 3 years, $132.00 ($27.50—U.S ...
Dexmethylphenidate (Focalin - Novartis), a new formulation of methylphenidate (Ritalin, and others) is now available for treatment of attention deficit/hyperactivity disorder (ADHD). Dexmethylphenidate is the d-threo-enantiomer of racemic methylphenidate. "Now the right half may be all your patients need," said a recent ad. Focalin is the third new methylphenidate formulation marketed in the last two years.
Beta Interferons for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Oct 14, 2002 (Issue 1141)
BETA INTERFERONS FOR MS
Drug Dosage Cost
1
Interferon β-1a − Avonex (Biogen) 30 µg weekly IM $12,808 ...
Three beta interferons are widely used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).
Rasburicase (Elitek) for Hyperuricemia
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002 (Issue 1143)
*
Allopurinol
generic 150-300 mg PO $ 1.82
Zyloprim (Prometheus) 2.20
Aloprim (Nabi) 200 mg/m
2
IV 1290.00 ...
Rasburicase (Elitek - Sanofi-Synthelabo), a recombinant form of urate oxidase derived from the fungus Aspergillus flavus, has been approved by the FDA for intravenous (IV) management of hyperuricemia associated with tumor lysis syndrome in pediatric patients.
Drug-eluting Stents
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003 (Issue 1152)
(SIRIUS) randomized 1,101 patients with previously untreated coronary lesions, including some with longer ...
Most angioplasty procedures for coronary artery disease now include placement of stents, which have improved both short- and long-term success rates. The main limitation is restenosis, which occurs in about 25% of patients. Drug-eluting stents intended to reduce the incidence of restenosis have been approved for use in Europe, but not yet in the US.
Cinacalcet (Sensipar)
The Medical Letter on Drugs and Therapeutics • Sep 20, 2004 (Issue 1192)
concentrations.
1
CLINICAL STUDIES — Three placebo-controlled clinical trials in patients ...
Cinacalcet hydrochloride (Sensipar - Amgen) has been approved by the FDA for treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on dialysis and treatment of hypercalcemia in patients with parathyroid carcinoma.
Clarification: Hand Hygiene and CDAD
The Medical Letter on Drugs and Therapeutics • Jan 29, 2007 (Issue 1253)
will not eradicate C.
difficile spores.”
1
One reader pointed out that alcoholbased products do eradicate some C ...
In the recent Medical Letter article on the treatment of Clostridium difficile–associated disease (CDAD) we wrote: “Healthcare workers caring for patients with C. difficile infection should follow contact isolation precautions, especially use of gloves and hand washing with soap and water after glove removal. Alcohol-based products such as hand sanitizers will not eradicate C. difficile spores.”1 One reader pointed out that alcoholbased products do eradicate some C. difficile spores and have been invaluable against other pathogens.In an unpublished study available as an abstract, both...